Latest News
Researchers, led by Thazin Nwe Aung, PhD, in the laboratory of David Rimm, MD, PhD, have developed a way to predict how lung cancer cells will respond to different therapies, allowing people with the most common form of lung cancer to receive more effective individualized treatment.
- October 03, 2025Source: Cancer Network
Regarding finding the right drug for the right patient, the reality of cancer management is far more complex than a single genetic mutation, according to David Rimm, MD, PhD.
- October 03, 2025Source: Cancer Network
It may be time for precision medicine to expand beyond the genomics realm and enter the protein space in the management of melanoma and other cancers, according to David Rimm, MD, PhD.
- October 01, 2025Source: Cancer Network (with Dr. David Rimm)
Dr. David Rimm spoke with Cancer Network on his latest research.
- September 30, 2025Source: Cancer Network
In an interview with CancerNetwork®, Thazin Nwe Aung, PhD, an associate research scientist in Pathology at the Yale School of Medicine and Yale Cancer Center, discussed strategies for overcoming resistance to immunotherapy and other drugs among patients with melanoma.
- September 29, 2025Source: Cancer Network
According to Thazin Nwe Aung, PhD, an artificial intelligence (AI)–driven assessment for scoring tumor-infiltrating lymphocytes (TILs) may help better predict melanoma prognoses vs pathologist scoring. Aung, an associate research scientist in Pathology at the Yale School of Medicine, spoke with CancerNetwork® about the publication of a multi-institutional prognostic study she authored in JAMA Network Open that compared pathologist-read vs AI-driven assessments of TILs among patients with melanoma.
- August 25, 2025Source: WTNH
David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and professor of medicine at Yale School of Medicine, discussed two important developments to come out of his lab.
- August 20, 2025Source: NBC Connecticut (with Dr. David Rimm and Thazin Aung)
Yale Cancer Center researchers are trying to figure out if artificial intelligence can help people with cancer. They found that AI-based scoring of melanoma tumor-infiltrating immune cells, significantly outperforms traditional pathologist eyeballing.
- August 04, 2025Source: Healio (with Dr. David Rimm)
Yale Cancer Center researcher David Rimm, MD, PhD, who is the Anthony N. Brady Professor of Pathology, and colleagues developed a novel assay to measure HER2 and TROP2 levels in patients with breast cancer. These data could help physicians decide which antibody-drug conjugates should be used in each individual case.
- July 31, 2025Source: News 12 Connecticut
Researchers at Yale say AI computers can now outperform people at tasks that previously relied on the human eye, leading to faster and more accurate decision-making throughout melanoma treatment.